Neutralizing antibodies for HIV-1 prevention
B Julg, DH Barouch - Current Opinion in HIV and AIDS, 2019 - journals.lww.com
B Julg, DH Barouch
Current Opinion in HIV and AIDS, 2019•journals.lww.comEncouraging results from preclinical and clinical studies support the development of bNAbs
for prevention and a number of antibodies with exceptional breadth and potency are
available for clinical evaluation. Further optimization of viral coverage and antibody half-life
will accelerate the clinical implementation of bNAbs as a critical tool for HIV-1 prevention
strategies.
for prevention and a number of antibodies with exceptional breadth and potency are
available for clinical evaluation. Further optimization of viral coverage and antibody half-life
will accelerate the clinical implementation of bNAbs as a critical tool for HIV-1 prevention
strategies.
Summary
Encouraging results from preclinical and clinical studies support the development of bNAbs for prevention and a number of antibodies with exceptional breadth and potency are available for clinical evaluation. Further optimization of viral coverage and antibody half-life will accelerate the clinical implementation of bNAbs as a critical tool for HIV-1 prevention strategies.
Lippincott Williams & Wilkins